Dyslipidemia, therefore, can be used as a biomarker of IR even in those individuals treated with “statins” (HMG-CoA reductase inhibitors), as they have an important reduction in LDL-cholesterol with a smaller impact in the TG/HDL ratio. This evidence concerns the gene HMGCR and metabolic syndrome.